问道CLDN18.2：Narikazu Boku教授中国行圆满收官，聆听世界声轨，共谱东方和鸣

*仅供医学专业人士阅读参考

点击视频观看Boku教授中国行精彩内容

参考文献：

[1] 中国抗癌协会胃癌专业委员会. 胃癌抗HER2治疗中国专家共识（2024年版）. 中国肿瘤临床, 2024, 51(23): 1189-1205.

[2] Chen Y, et al. The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis. J Hematol Oncol. 2025 Apr 15;18(1):42.

[3] Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023;8(1):100762.

[4] European Medicines Agency. Assessment report for Opdivo (nivolumab) [EB/OL]. (2023-10-05) [2025-10-30].

[5] Shitara K,et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023 May 20;401(10389):1655-1668.

[6] Shah MA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023 Aug;29(8):2133-2141.

[7] Pharmaceuticals and Medical Devices Agency (PMDA). Review Report for Vyloy (Zolbetuximab)[R/OL]. 2024.

[8] Japan Society of Clinical Oncology (JSCO). 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol. 2024.

[9] Liu J, Yang J, Sun Y, et al. CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nat Med. 2025; 31(7):961-968.

*此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场。